Press Releases

Press Releases

May 2, 2019
CytomX Therapeutics to Announce First Quarter 2019 Financial Results
-Teleconference Scheduled for May 9, 2019, at 5:00 p.m. ET- SOUTH SAN FRANCISCO, Calif. , May 02, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on
Additional Formats
March 25, 2019
CytomX Therapeutics Announces Transition of Chief Financial Officer
SOUTH SAN FRANCISCO, Calif. , March 25, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platform, today
Additional Formats
March 5, 2019
CytomX to Present at Upcoming Healthcare Conferences
SOUTH SAN FRANCISCO, Calif. , March 05, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on our Probody™ therapeutic technology platform, announced
Additional Formats
February 27, 2019
CytomX Therapeutics Announces Full-Year 2018 Financial Results
Company to Host a Conference Call Today, February 27, 2019, at 5:00 p.m. EST / 2:00 p.m. PST SOUTH SAN FRANCISCO, Calif. , Feb. 27, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of
Additional Formats
February 26, 2019
CytomX Therapeutics 2019 Research and Development Day Highlights Clinical Data from Lead Programs and the Broad Potential of Probody™ Therapeutic Platform
- CX-2009, a First-in-Class Probody Drug Conjugate Targeting CD166, Demonstrates Encouraging Anti-Cancer Activity in Multiple Tumor Types and Safety in Phase 1 Dose Escalation - - CX-072, A Potentially Differentiated Anti-PD-L1 Agent, Shows Favorable Anti-Cancer Activity in Multiple Tumor Types as
Additional Formats
February 14, 2019
CytomX Therapeutics to Announce Full-Year 2018 Financial Results
-Teleconference Scheduled for February 27, 2019 , at 5:00 p.m. ET - -Company to Host Research and Development Day on February 26, 2019 in New York City - SOUTH SAN FRANCISCO, Calif. , Feb. 14, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncology-focused
Additional Formats
Displaying 11 - 20 of 23